Anacor appoints Paul L. Berns as CEO, effective immediately Berns succeeds David P. Perry who has served as Anacorís (ANAC) President and CEO since 2002. Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies. He most recently served as the President and Chief Executive Officer of Allos Therapeutics prior to its acquisition by Spectrum Pharmaceuticals (SPPI) in 2012.
Anacor initiated with a Neutral at Goldman Goldman Sachs views Anacor Pharmaceuticals as an attractive dermatology name, but finds the stock fairly valued at current levels. The firm started shares with a Neutral rating and $36 price target.